Success Metrics

Clinical Success Rate
85.0%

Based on 17 completed trials

Completion Rate
85%(17/20)
Active Trials
5(17%)
Results Posted
29%(5 trials)
Terminated
3(10%)

Phase Distribution

Ph phase_4
2
7%
Ph phase_1
6
21%
Ph not_applicable
2
7%
Ph phase_2
17
59%
Ph phase_3
2
7%

Phase Distribution

6

Early Stage

17

Mid Stage

4

Late Stage

Phase Distribution29 total trials
Phase 1Safety & dosage
6(20.7%)
Phase 2Efficacy & side effects
17(58.6%)
Phase 3Large-scale testing
2(6.9%)
Phase 4Post-market surveillance
2(6.9%)
N/ANon-phased studies
2(6.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.0%

17 of 21 finished

Non-Completion Rate

19.0%

4 ended early

Currently Active

5

trials recruiting

Total Trials

29

all time

Status Distribution
Active(5)
Completed(17)
Terminated(4)
Other(3)

Detailed Status

Completed17
Recruiting3
Terminated3
unknown3
Active, not recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
29
Active
5
Success Rate
85.0%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (20.7%)
Phase 217 (58.6%)
Phase 32 (6.9%)
Phase 42 (6.9%)
N/A2 (6.9%)

Trials by Status

withdrawn13%
recruiting310%
completed1759%
terminated310%
unknown310%
active_not_recruiting27%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT05986292Phase 2

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Recruiting
NCT06983223Not Applicable

Oral Sucrosomial® Vitamin B12 in the Management of B12 Deficiency Among Metformin-Treated Type 2 Diabetes Patients

Completed
NCT06847399Phase 2

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

Recruiting
NCT03953118Phase 4

Azithromycin for Meibomian Gland Disease

Terminated
NCT02711553Phase 2

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Active Not Recruiting
NCT06982183Phase 4

The Effects of Propranolol, Hydrocortisone, and Morphine on Military-Relevant Performance Outcomes

Recruiting
NCT02919579Phase 1

A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder

Completed
NCT04827537Phase 2

Anti-protozoal Effect of Steroid Hormone 20-hydroxyecdysone

Active Not Recruiting
NCT03475225Phase 3

Vitamine D in Drug Resistant Epilepsy

Completed
NCT01561690Phase 2

A Study of ARRY-502 in Patients With Persistent Asthma

Completed
NCT04202211Phase 2

FMT for Remission of Active Ulcerative Colitis in Adults

Withdrawn
NCT04874324Phase 1

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349

Completed
NCT04583358Phase 2

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

Unknown
NCT05372939Phase 2

Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)

Completed
NCT00790049Phase 1

A Safety Study of ARRY-371797 in Healthy Subjects

Completed
NCT00542035Phase 2

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

Completed
NCT00663767Phase 2

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

Completed
NCT00650767Phase 2

A Study of ARRY-438162 in Patients With Rheumatoid Arthritis

Completed
NCT00811499Phase 2

A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis

Terminated
NCT01366014Phase 2

A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee

Completed

Drug Details

Intervention Type
DRUG
Total Trials
29